Home › Iron Deficiencies › NCT07156526
Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life
Safety and Efficacy of Two Qualia Iron Formulations on Iron Biomarkers and Quality of Life: A Double-Blind Pilot Study
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text * Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly * Willing to complete questionnaires, records, and diaries associated with the study. * If the participant responded "Yes" to ≥2 questions on the custom Iron Inadequacy Questionnaire. Preference will be given to participants with a higher score. * If a participant has the following: Ferritin 30 ng/mL (anything under 50 ng/mL is considered suboptimal, but participants with 30 ng/mL will be prioritized) Exclusion Criteria: * Women who are pregnant, breastfeeding, or planning to become pregnant during the trial * Known food intolerances/allergy to any ingredients in the product * Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, irritable bowel disease, cancer * Having had a significant cardiovascular event in the past 6 months * Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines * On immunosuppressive therapy * Individuals who were deemed incompatible with the test protocol * Adults lacking capacity to consent * Individuals taking any of the following medications: Antacids Proton pump inhibitors (PPIs) Antipsychotics Antibiotics
About the study
This double-blind parallel pilot study will evaluate the safety and efficacy of two Qualia Iron formulations versus placebo in approximately 40 healthy adults (aged 18+) over a 56-day period. Approximately 40 participants will be assigned to three study arms: Qualia Iron Version 1, 2, (n=15 each) or a Placebo (n=10). Each participant will take one or two capsules once daily in the morning, with or without food. The supplementation regimen is a 5 days on, 2 days off protocol, and goes for 56 days (8 weeks). The primary outcomes of this study are to assess between-group changes in iron status biomarkers. Secondary outcomes include within-group changes in iron status biomarkers, safety and tolerability as measured by a custom Safety and Tolerability survey, and RAND SF-36 quality of life scores.
What is being tested
- Qualia Iron Version A (dietary supplement)
- Qualia Iron Version B (dietary supplement)
- Placebo (dietary supplement)
Sponsor: Qualia Life Sciences · Participants: 40 · Started: Jun 18, 2026
Contact the study team
- William Scuba · Phone: 855-281-2328
Official record on ClinicalTrials.gov — NCT07156526
Locations in the U.S.
| California | Qualia Life Sciences, Carlsbad |
Conditions
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.